查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1751261

亨廷顿氏舞蹈症治疗市场规模、份额、趋势分析报告：按治疗、分销管道、地区和细分市场预测，2025 年至 2030 年

Huntington's Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

亨廷顿氏舞蹈症治疗市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球亨廷顿氏舞蹈症治疗市场规模预计到2030年将达到18.712亿美元，2025年至2030年的复合年增长率为23.8%。

这一增长得益于对新产品研发的高投入、合作研究以及西方国家亨廷顿舞蹈症的高负担。亨廷顿舞蹈症是一种罕见的遗传性神经退化性疾病，影响几代。此病在30至50岁之间发病，会损害患者工作和照顾家庭的能力，最终导致患者无法进行日常活动。

不同地理位置的盛行率差异超过10倍，可能与病例确认和诊断标准的差异有关。不同地理位置的盛行率差异超过10倍，可能与病例确认和诊断标准的差异有关。因此，一般人群中復发性肥大的盛行率可能高于预期。亚洲的盛行率一直较低，而北美和澳洲的盛行率较高。

Neurocrine Biosciences 和 Azevan Pharmaceuticals 等大型公司专注于亨廷顿舞蹈症（HD）症状治疗的研发。 Azevan Pharmaceuticals 正在开发 SRX246，作为一种实验性药物，用于治疗亨廷顿舞蹈症的神经精神症状。 SRX246 透过阻断大脑中的加压素 1a (V1a) 受体来发挥作用。在神经系统中，V1a 受体是主要的加压素受体。透过阻断 V1a 受体，SRX246 可以限制加压素与此受体结合，从而避免亨廷顿舞蹈症患者出现易怒和攻击性行为。

然而，目前核准的药物仅限于症状治疗或安宁疗护，而非针对疾病的根本病因。药物治疗虽然可以严重症状，但常伴随嗜睡、步态障碍、吞嚥障碍和嗜睡等副作用，严重影响患者的生活品质。鑑于该疾病尚无明确的治疗方法，评估这些患者的健康相关生活品质 (HRQOL) 受到的影响至关重要。处于疾病早期至中期的亨廷顿氏症 (HD) 患者需要多学科医疗服务，包括认知评估和咨询。

亨廷顿舞蹈症（HD）的药物开发面临巨大障碍，一些治疗方法未能证明疗效或伴随显着毒性。 2020年9月，Vaccinex Inc. 的 pepinemab 的一项 II 期研究未能达到早期症状型和前驱型亨廷顿舞蹈症患者的预设共同主要终点。在 SIGNAL 研究中，两个共同主要终点（两个认知结局，即亨廷顿舞蹈症认知评估系统和临床总体印象变化 (CGIC)）在早期症状人群中未达到统计学意义。

亨廷顿氏舞蹈症治疗市场报告重点

  • 由于产品供应充足且专利保护到位，预计对症治疗领域将在2024年占据最大收入份额。由于SAGE-718和Cellavita-HD的进入，疾病修正治疗预计将成为预测期内成长最快的领域。
  • 目前，各公司并不专注于针对突变蛋白，而是专注于开发可直接注射到大脑中以直接阻止突变 HTT 蛋白形成的治疗方法。
  • 处于早期开发阶段的具有新标靶的药物包括 Cellavita 和 Azidus Brazil 的 Cellavita HD（干细胞疗法）、Sangamo Therapeutics 的 mHTT ZFP（锌指蛋白）和 UniQure 的 AMT-130（基因疗法）。
  • 预计北美将在 2024 年占据最高的收益占有率，而由于该地区拥有庞大的报销机构和较高的 HD 负担，预计美国和加拿大将在预测期内主导市场。

目录

第一章调查方法与范围

第二章执行摘要

第三章市场变数、趋势和范围

  • 市场展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 亨丁顿舞蹈症治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • 定价分析
    • 管道分析

第四章 亨廷顿舞蹈症治疗市场：治疗评估与趋势分析

  • 全球亨廷顿舞蹈症治疗市场：治疗仪表板
  • 全球亨廷顿氏舞蹈症治疗市场：治疗变异分析
  • 亨丁顿舞蹈症治疗市场（依治疗方法、收益）
  • 治疗
  • 疾病修正治疗

第五章亨廷顿氏舞蹈症治疗市场：通路评估与趋势分析

  • 全球亨廷顿舞蹈症治疗市场：分销通路仪表板
  • 全球亨廷顿舞蹈症治疗市场：通路变化分析
  • 亨廷顿氏舞蹈症治疗市场（按分销管道和收益）
  • 医院药房
  • 零售药局
  • 网路药局

第六章 亨廷顿舞蹈症治疗市场：按治疗、应用和分销管道分類的区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第七章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • 2024 年主要公司市占率分析
    • H. Lundbeck A/S.
    • Teva Pharmaceutical Industries Ltd.
    • Bausch Health Companies Inc.
    • Hetero
    • Lupin
    • Hikma Pharmaceuticals PLC
    • Dr. Reddy's Laboratories Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • uniQure NV.
    • Latus Bio
Product Code: GVR-2-68038-552-6

Huntington's Disease Treatment Market Growth & Trends:

The global huntington's disease treatment market size is expected to reach USD 1,871.2 million by 2030, registering a CAGR of 23.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is due to high R&D investments for new product development, research collaboration, and the high HD burden in western countries. Huntington's disease is a rare inherited neurodegenerative disease that affects several generations. It affects people between the ages of 30 and 50, impairing their capacity to work, care for their families, and, eventually, complete daily tasks.

The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. The prevalence varies by more than ten-fold between geographical locations, which can be related to variations in case ascertainment and diagnostic criteria. As a result, the prevalence of enlarged repetitions in the general population may be greater than expected. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence.

The key players, such as Neurocrine Biosciences, Inc. and Azevan Pharmaceuticals, Inc., are focusing on research and development of symptomatic therapies for HD. Azevan Pharmaceuticals is developing SRX246 as an experimental drug to treat neuropsychiatric symptoms in Huntington's disease. SRX246 is a drug that works by blocking the vasopressin 1a (V1a) receptor in the brain. In the neurological system, V1a receptor is the major vasopressin receptor. SRX246 works by inhibiting the V1a receptor, restricting vasopressin from attaching to the receptor, and generating irritable and aggressive behavior, which is seen in Huntington's disease patients.

However, currently approved drugs provide symptomatic and palliative care and do not target the underlying cause of the disease. While medications can decrease the severity of symptoms, they are often associated with adverse effects such as somnolence, gait issues, dysphagia, and apathy, which can have serious impacts on a patient's quality of life. Given the lack of a cure for the disease, it is critical to evaluate how Health-related Quality of Life (HRQOL) is affected in these patients. HD patients in early to middle stages of the disease need coordinated multidisciplinary healthcare services, including assessment of cognitive function and counseling.

Drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. Vaccinex Inc.'s phase II trial of Pepinemab failed to satisfy pre-specified co-primary endpoints in patients with early manifest and prodromal HD, in September 2020. The two co-primary endpoints-a family of two cognitive evaluations from the Huntington's disease Cognitive Assessment Battery and Clinical Global Impression of Change (CGIC)-did not attain statistical significance in the early manifestation population in the SIGNAL study.

Huntington's Disease Treatment Market Report Highlights:

  • The symptomatic treatment segment accounted for the largest revenue share in 2024 owing to the product availability and patent protection. Disease-modifying therapies is anticipated to be the fastest-growing segment over the forecast years due to the entry of SAGE-718, and Cellavita-HD
  • Companies are now focusing on the development of treatments that can be injected directly into the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
  • Drugs with novel targets in early-phase development include Cellavita and Azidus Brazil's Cellavita HD (stem cell therapy), Sangamo Therapeutics, Inc. mHTT ZFP (zinc finger protein), and UniQure's AMT-130 (gene therapy)
  • North America held the highest revenue share in 2024 and is expected to dominate the market over the forecast period due to better reimbursement facilities and the high burden of HD in the U.S. and Canada

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Distribution Channel
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment and Distribution Channel Outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising anti-aging burden
      • 3.2.1.2. Advancements in drug development
      • 3.2.1.3. Growing awareness about anti-aging treatment
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of development
      • 3.2.2.2. Regulatory challenges for new drug approvals
  • 3.3. Huntington's Disease Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Huntington's Disease Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Huntington's Disease Treatment Market: Treatment Dashboard
  • 4.2. Global Huntington's Disease Treatment Market: Treatment Movement Analysis
  • 4.3. Global Huntington's Disease Treatment Market by Treatment, Revenue
  • 4.4. Symptomatic Treatment
    • 4.4.1. Symptomatic Treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.5. Disease-modifying Therapies
    • 4.5.1. Disease-modifying Therapies market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Huntington's Disease Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Global Huntington's Disease Treatment Market: Distribution Channel Dashboard
  • 5.2. Global Huntington's Disease Treatment Market: Distribution Channel Movement Analysis
  • 5.3. Global Huntington's Disease Treatment Market by Distribution Channel, Revenue
  • 5.4. Hospital Pharmacy
    • 5.4.1. Hospital Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.5. Retail Pharmacy
    • 5.5.1. Retail Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.6. Online Pharmacy
    • 5.6.1. Online Pharmacy market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. Huntington's Disease Treatment Market: Regional Estimates & Trend Analysis by Treatment, Application, and Distribution Channel

  • 6.1. Regional Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Thailand
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company market share analysis, 2024
    • 7.3.4. H. Lundbeck A/S.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Product benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Teva Pharmaceutical Industries Ltd.
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Treatment benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. Bausch Health Companies Inc.
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Product benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Hetero
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Product benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Lupin
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Product benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Hikma Pharmaceuticals PLC
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Product benchmarking
      • 7.3.9.4. Strategic initiatives
    • 7.3.10. Dr. Reddy's Laboratories Ltd.
      • 7.3.10.1. Company overview
      • 7.3.10.2. Financial performance
      • 7.3.10.3. Product benchmarking
      • 7.3.10.4. Strategic initiatives
    • 7.3.11. Sun Pharmaceutical Industries Ltd.
      • 7.3.11.1. Company overview
      • 7.3.11.2. Financial performance
      • 7.3.11.3. Product benchmarking
      • 7.3.11.4. Strategic initiatives
    • 7.3.12. Novartis AG
      • 7.3.12.1. Company overview
      • 7.3.12.2. Financial performance
      • 7.3.12.3. Product benchmarking
      • 7.3.12.4. Strategic initiatives
    • 7.3.13. uniQure NV.
      • 7.3.13.1. Company overview
      • 7.3.13.2. Financial performance
      • 7.3.13.3. Product benchmarking
      • 7.3.13.4. Strategic initiatives
    • 7.3.14. Latus Bio
      • 7.3.14.1. Company overview
      • 7.3.14.2. Financial performance
      • 7.3.14.3. Product benchmarking
      • 7.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 3 North America Huntington's Disease Treatment Market, by Distribution Channel 2018 - 2030 (USD Million)
  • Table 4 U.S. Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 5 U.S. Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 Canada Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 7 Canada Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 Mexico Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 9 Mexico Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 Europe Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 11 Europe Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Germany Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 13 Germany Huntington's Disease Treatment Market, by Application, 2018 - 2030 (USD Million)
  • Table 14 UK Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 15 UK Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 France Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 17 France Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 Italy Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 19 Italy Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Spain Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 21 Spain Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 Asia Pacific Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 23 Asia Pacific Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 China Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 25 China Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 26 Japan Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 27 Japan Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 India Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 29 India Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 South Korea Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 31 South Korea Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 32 Latin America Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 33 Latin America Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Brazil Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 35 Brazil Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 MEA Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 37 MEA Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 38 South Africa Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 39 South Africa Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Saudi Arabia Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 41 Saudi Arabia Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 UAE Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 43 UAE Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 44 Kuwait Huntington's Disease Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 45 Kuwait Huntington's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Huntington's Disease Treatment Market Segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and Distribution Channel segment snapshot
  • Fig. 10 Distribution Channel segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Huntington's Disease Treatment market: Treatment outlook and key takeaways
  • Fig. 17 Huntington's Disease Treatment market: Treatment movement analysis
  • Fig. 18 Symptomatic Treatment market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Disease-modifying Therapies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Huntington's Disease Treatment market: Distribution Channel outlook and key takeaways
  • Fig. 21 Huntington's Disease Treatment Market: Distribution Channel movement analysis
  • Fig. 22 Hospital Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Retail Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Online Pharmacy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Huntington's Disease Treatment market revenue, by region, 2024 & 2030, (USD million)
  • Fig. 26 Regional marketplace: Key takeaways
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Key country dynamics
  • Fig. 30 Target disease prevalence
  • Fig. 31 U.S. Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Key country dynamics
  • Fig. 33 Target disease prevalence
  • Fig. 34 Canada Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Mexico Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Key country dynamics
  • Fig. 37 Target disease prevalence
  • Fig. 38 Europe Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Target disease prevalence
  • Fig. 41 UK Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 Target disease prevalence
  • Fig. 44 Germany Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Key country dynamics
  • Fig. 46 Target disease prevalence
  • Fig. 47 France Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 Spain Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Target disease prevalence
  • Fig. 53 Italy Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Target disease prevalence
  • Fig. 56 Denmark Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Key country dynamics
  • Fig. 58 Target disease prevalence
  • Fig. 59 Sweden Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Key country dynamics
  • Fig. 61 Target disease prevalence
  • Fig. 62 Norway Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Target disease prevalence
  • Fig. 66 Japan Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Target disease prevalence
  • Fig. 69 China Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Target disease prevalence
  • Fig. 72 India Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Target disease prevalence
  • Fig. 75 Australia Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Thailand Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Key country dynamics
  • Fig. 79 South Korea Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Target disease prevalence
  • Fig. 83 Brazil Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Target disease prevalence
  • Fig. 86 Argentina Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 MEA Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Key country dynamics
  • Fig. 89 Target disease prevalence
  • Fig. 90 South Africa Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Target disease prevalence
  • Fig. 93 Saudi Arabia Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Key country dynamics
  • Fig. 95 Target disease prevalence
  • Fig. 96 UAE Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Target disease prevalence
  • Fig. 99 Kuwait Huntington's disease treatment market estimates and forecasts, 2018 - 2030 (USD Million)